A Phase 3 interventional study of S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm) and Fluorouracil/cisplatin (control arm) in Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction, sponsored by Taiho Oncology, Inc.. Terminated at 87 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing tegafur in Stomach Neoplasms — 10 open to participants now, 11 under way, 1 of them phase 3. Tegafur · Stomach Neoplasms.
Among the 65 studies testing tegafur in Stomach Neoplasms, this one is the 10th largest by enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2011, is one of 13 in phase 3, and was the 26th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →10 of the 65 studies testing tegafur in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18–80
Jinbo Yue · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Tegafur: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 46 · Phase 3 17
First in 2001; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 361 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 62 across the 64 interventional studies. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taiho Oncology, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd.: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd., this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2011, is one of 8 in phase 3, and was the 9th registered.
Otsuka Holdings Co., Ltd.’s Stomach Neoplasms studies by the year they started, since 1997.
3 of the studies testing tegafur in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07304258Hebei Medical UniversityA Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10 | 2026-12-31 |
| NCT06519591Ruijin HospitalSystemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis | 2027-01 |
| NCT05184803Asan Medical CenterA Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing tegafur in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 14 in Stomach Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously untreated with chemotherapy.
This is an open-label, international, Phase 3 study evaluating the efficacy and safety of the S-1/cisplatin regimen versus the 5-FU/cisplatin regimen in chemotherapy-naïve patients with metastatic diffuse gastric carcinoma including carcinoma of the gastro-esophageal junction. Patients will be randomly assigned to S-1/cisplatin (experimental regimen, Arm A) or 5-FU/cisplatin (control regimen, Arm B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received S-1 25 milligrams per meter square (mg/m\^2) orally twice daily (BID) every 12 hours from Day 1 through Day 21, 1 hour before or after meal with a glass of water; followed by a 7-day rest period from Day 22 to Day 28 in a 28-day cycle. Participants received a single dose of cisplatin 75 mg/m\^2 as a 1- to 3-hour intravenous (IV) infusion on Day 1 following the morning dose of S-1 for a maximum of 8 cycles (each cycle of 28 days). Participants received study medication until progression of disease (PD), adverse event (AE), withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
Drug: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)
Participants received 5-Fluorouracil (5-FU) 800 mg/m\^2 per 24 hours as continuous IV infusion over 120 hours from Day 1 through Day 5 followed by a 16-day rest period on Days 6 through 21 in a 21-day cycle. Participants received a single dose of cisplatin 80 mg/m\^2 as a 1- to 3-hour IV infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles (each cycle of 21 days). Participants received study medication until PD, AE, withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
Drug: Fluorouracil/cisplatin (control arm)
Drug pages: Tegafur · Gimeracil · Oxonic Acid · Cisplatin
25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
Also known as: TS-1, Tegafur+Gimeracil+Oteracil
Drug pages: Tegafur · Gimeracil · Oxonic Acid
5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
Also known as: TS-1, Tegafur+Gimeracil+Oteracil
Overall Survival (OS)
OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method.
Time frame: From the date of randomization until disease progression or death, cut-off date: 15 August 2014 (approximately 40 months)
Progression-free Survival (PFS)
PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method.
Time frame: From date of randomization until disease progression or death, cut-off date: 07 March 2014 (approximately 34.7 months)
Time to Treatment Failure (TTF)
TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment.
Time frame: From date of randomization until disease progression, cut-off date: 07 March 2014 (approximately 34.7 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)
AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication \[maximum duration: 35.7 months\]).
Time frame: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3
An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication \[maximum duration: 35.7 months\]).
Time frame: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
Overall Response Rate (ORR): Percentage of Participants With Overall Response
ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (\<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference.
Time frame: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
Duration of Response (DR)
Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to \<10 mm. Analysis was performed by using Kaplan-Meier method.
Time frame: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
Time to Tumor Response (TTR)
TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to \<10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method.
Time frame: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
A total of 690 participants were screened from 14 April 2011 to 25 February 2014, of which 361 participants enrolled in the study. The data cut-off date for all clinical data except overall survival was 07 Mar 2014 and for overall survival was 15 Aug 2014. The participants were randomized using interactive Voice/Web randomization system(2:1 ratio) to receive S-1/cisplatin or 5-Fluorouracil (5-FU)/cisplatin. A total of 329 participants failed screening due to failure to meet inclusion criteria.
| Milestone | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| Started | 239 | 122 |
| Treated | 238 | 121 |
| As treated (at) population | 230 | 118 |
| Completed | 0 | 0 |
| Not completed | 239 | 122 |
| Withdrew: Death | 173 | 90 |
| Withdrew: Lost to follow-up | 6 | 2 |
| Withdrew: Withdrew consent | 6 | 1 |
| Withdrew: Sponsor study termination | 23 | 13 |
| Withdrew: Randomized but not treated | 1 | 1 |
| Withdrew: Study follow-up ongoing | 28 | 14 |
| Withdrew: Sponsor decision | 2 | 1 |
OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method.
| months | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| Overall Survival (OS) | 7.5 (6.7 to 9.3) | 6.6 (5.7 to 8.1) |
PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method.
| months | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| Progression-free Survival (PFS) | 4.4 (3.8 to 5.6) | 3.9 (3.6 to 5.2) |
TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment.
| months | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| Time to Treatment Failure (TTF) | 4.2 (3.8 to 4.9) | 3.8 (3.4 to 4.3) |
AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication \[maximum duration: 35.7 months\]).
| Participants | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| TEAE | 214 | 111 |
| TESAE | 63 | 31 |
An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication \[maximum duration: 35.7 months\]).
| Participants | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3 | 157 | 78 |
ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (\<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference.
| percentage of participants | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| Overall Response Rate (ORR): Percentage of Participants With Overall Response | 34.7 (28.0 to 41.9) | 19.8 (12.2 to 29.4) |
Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to \<10 mm. Analysis was performed by using Kaplan-Meier method.
| months | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| Duration of Response (DR) | 5.1 (3.0 to 5.8) | 4.2 (2.0 to 6.0) |
TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to \<10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method.
| months | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| Time to Tumor Response (TTR) | 1.8 (1.8 to 1.9) | 1.9 (1.8 to 2.1) |
Collected over AEs were collected from first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months). Deaths were collected from Baseline up to end of study (up to approximately 40 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| S-1+Cisplatin | 173/239 (72.4%) | 63/230 (27.4%) | 210/230 (91.3%) |
| 5FU+Cisplatin | 90/122 (73.8%) | 31/118 (26.3%) | 110/118 (93.2%) |
| Event | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 11/230 | 5/118 |
| Gastric haemorrhageGastrointestinal disorders | 3/230 | 4/118 |
| VomitingGastrointestinal disorders | 5/230 | 4/118 |
| DehydrationMetabolism and nutrition disorders | 6/230 | 4/118 |
| HypokalaemiaMetabolism and nutrition disorders | 0/230 | 4/118 |
| Renal failure acuteRenal and urinary disorders | 5/230 | 1/118 |
| DysphagiaGastrointestinal disorders | 4/230 | 1/118 |
| NauseaGastrointestinal disorders | 4/230 | 1/118 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/230 | 2/118 |
| HaematemesisGastrointestinal disorders | 1/230 | 2/118 |
| Event | S-1+Cisplatin | 5FU+Cisplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 122/230 | 62/118 |
| AnaemiaBlood and lymphatic system disorders | 97/230 | 49/118 |
| Decreased appetiteMetabolism and nutrition disorders | 95/230 | 40/118 |
| NeutropeniaBlood and lymphatic system disorders | 68/230 | 43/118 |
| VomitingGastrointestinal disorders | 82/230 | 34/118 |
| AstheniaGeneral disorders | 55/230 | 36/118 |
| FatigueGeneral disorders | 59/230 | 28/118 |
| DiarrhoeaGastrointestinal disorders | 41/230 | 22/118 |
| Abdominal painGastrointestinal disorders | 42/230 | 12/118 |
| Weight decreasedInvestigations | 40/230 | 18/118 |
The Intent-to-Treat (ITT) population included all randomized participants including those not dosed according to their randomization.
| Age, Continuous(years) | S-1+Cisplatin | 5FU+Cisplatin | Total |
|---|---|---|---|
| Mean | 55.1 ± 11.01 | 55.8 ± 11.80 | 55.4 ± 11.27 |
| Sex: Female, Male(Participants) | S-1+Cisplatin | 5FU+Cisplatin | Total |
|---|---|---|---|
| Female | 115 | 62 | 177 |
| Male | 124 | 60 | 184 |
| Race/Ethnicity, Customized(Participants) | S-1+Cisplatin | 5FU+Cisplatin | Total |
|---|---|---|---|
| Caucasian/White | 226 | 117 | 343 |
| Black | 4 | 2 | 6 |
| Asian/Oriental | 4 | 0 | 4 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 3 | 3 | 6 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | S-1+Cisplatin | 5FU+Cisplatin | Total |
|---|---|---|---|
| ECOG Grade 0 | 75 | 38 | 113 |
| ECOG Grade 1 | 164 | 83 | 247 |
| Missing | 0 | 1 | 1 |
Ran from Apr 2011 to primary completion in Aug 2014, 40 months.
Results were first posted in May 2022, 7 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid · Cisplatin